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Abstract
Background: Increased incidence of papillary thyroid carcinoma (PTC) is observed as a consequence
of radiation exposure in connection to the Chornobyl nuclear plant accident in 1986. In this study,
we report a cohort of adult Ukrainian patients diagnosed with PTC from 2004 to 2008 following
exposure at the age of 18 years or younger.
Methods: In total, 70 patients were identiﬁed and clinically characterized. The common BRAF
1799TOA mutation was assessed by pyrosequencing, the RET/PTC1 and RET/PTC3 (NCOA4)
rearrangements by RT-PCR, and the expression of Ki-67 (MIB-1 index), BCL2, cyclin A, and cyclin D1
by immunohistochemistry.
Results: In total, 46/70 (66%) cases carried a BRAF mutation and/or a RET/PTC rearrangement.
A BRAF mutation was detected in 26 tumors, RET/PTC1 in 20 cases, and RET/PTC3 in four cases.
In four of these cases, BRAF mutation and RET/PTC rearrangement were coexisting. The BRAF
mutation was underrepresented among PTCs with accompanying chronic lymphocytic thyroiditis
(CLT) compared with PTCs without this feature (12 vs 44%). MIB-1 proliferation index determined by
double staining with leukocyte common antigen was low (mean 0.8%; range 0.05–4.5%). Moreover,
increased expression of cyclin Awas observed in PTCs with a tumor size O2 cm compared with PTCs
%2 cm (1.2 vs 0.6%). BCL2 and cyclin D1 showed frequent expression but without associations to
clinical characteristics or ampliﬁcation of the CCND1 locus.
Conclusions: Our results suggest that this cohort has frequent BRAF mutation, RET/PTC1
rearrangement, and low proliferation index. Furthermore, BRAF 1799TOA was underrepresented
in PTCs with CLT, and cyclin A expression was associated with increased PTC tumor size.
European Journal of Endocrinology 166 1049–1060
Introduction
Papillary thyroid carcinoma (PTC) is the most common
type of endocrine cancer comprising up to 80% of all
malignant thyroid tumors (1). Increased incidence of
PTC was observed among Ukrainian children who were
exposed to radioactivity after the Chornobyl (Cher-
nobyl) nuclear plant accident in 1986 (2, 3). Speciﬁc
molecular and genetic features of such childhood PTC
have been described (4). Today, it is known that PTC
may also develop in adult individuals who were younger
than 18 years at the time of the accident and who lived
within the contaminated area (5, 6). Molecular changes
in such PTC have not been widely studied, and it is
presently unclear whether they have similar and/or
distinct molecular characteristics compared with PTC in
other populations.
PTC commonly exhibits a hotspot BRAF (v-raf
murine sarcoma viral oncogene homolog B1) mutation
or activation of the RET or NTRK genes through
different translocations that lead to abnormal tyrosine
kinase activity (4, 7). The common BRAF mutation
involves a thymine to adenine transversion at position
1799 (1799TOA) in exon 15, which results in an
activating missense substitution of valine to glutamic
acid at codon 600 (V600E) (4). The frequency of BRAF
mutation in PTC varies between studies from very low
frequencies up to 80% (8, 9, 10), and their presence
is reported to have prognostic implications (8). However,
a low prevalence of BRAF mutation was reported
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(9, 10, 11, 12).
Rearrangements of the RET proto-oncogene are
also frequently found in PTC and lead to expression
of chimerical transcripts termed RET/PTC due to
fusion of the tyrosine kinase domain of RET (TK-RET)
with various regions of other genes. RET/PTC1 and
RET/PTC3 are the most common forms of RET/PTC
constituting up to 90% of all RET rearrangements (13).
RET/PTC1 is the result of a translocation between the
coiled-coil domain-containing 6 gene (CCDC6) and TK-
RET, while fusion of the NCOA4 with TK-RET leads to
the formation of RET/PTC3. The frequency of reported
RET/PTC rearrangements varies largely between studies
(7, 12, 13, 14, 15). High frequencies of RET/PTC3 have
been reported in post-Chornobyl childhood PTC, in
contrast to adult PTC in which RET/PTC1 is more
common (13, 14, 15).
PTCs are also characterized by expression of certain
immunohistochemical markers such as Ki-67, BCL2,
cyclin A, and cyclin D1 involved in proliferation and
apoptosis. BCL2 is involved in blocking of apoptosis (16)
and cell survival (17),a n dBCL2 overexpression
correlates with PTC aggressiveness (18). Ki-67 is a
nuclear protein expressed in proliferating cells, and
the MIB-1 MAB against Ki-67 is used for determination
of the proliferation index (MIB-1 index). In PTC,
increased MIB-1 index has been associated with
a worse prognosis in some studies but not in others
(19, 20, 21, 22). Cyclin A activates cyclin-dependent
kinases to regulate proliferation and cell cycle pro-
gression through the S phase to the G2-M checkpoint
(23). Cyclin A expression has possible prognostic value
in breast cancer (24); however, its role in PTC has been
less studied (25, 26). Cyclin D1 is involved in cell cycle
control at the G1 checkpoint for progression from G1
to S phase. Expression of cyclin D1 is not observed
by immunohistochemistry in normal thyroid cells,
while its overexpression has been associated with
higher frequency of lymph node metastases (27, 28).
We have identiﬁed a cohort of 70 adult patients
with PTC who were exposed in their childhood or
as teenagers to the Chornobyl radioactive fallout
in 1986. Here, we describe the cohort concerning
clinical features, expression, and mutation data for
some established and some putative prognostic markers:
BRAF, RET/PTC1, RET/PTC3,M I B - 1i n d e x ,BCL2,
cyclin A, and cyclin D1.
Materials and methods
Patients and tissue samples
The 70 cases included in the study were identiﬁed from
patients surgically treated for a PTC from 2004 to 2008
in Kyiv City Teaching Endocrinological Center, Ukraine.
The standard surgical approach used for these patients
was total thyroidectomy followed bycentral lymph node
dissection. All patients in the cohort had been exposed
to radioactivity from the accident at the Chornobyl
nuclear power station in Ukraine in 1986, as
determined from the patients’ addresses and the
geographical pattern of the radioactive fallout. However,
data about radiation dosages are not available. At the
time of the accident, all patients were 18 years of age or
younger and lived near the most heavily contaminated
regions Kyiv, Chernihiv, or Zhitomyr (6).
Clinical datawere retrieved from medical records, and
archival formalin-ﬁxedparafﬁn-embedded (FFPE) tumor
tissue samples were collected for all cases. The tumors
were initiallyclassiﬁed as primary PTC, classical type, at
routine histopathological examination in Kyiv City
Teaching Endocrinological Center, whereby presence
or absence of coexisting chronic lymphocytic thyroiditis
(CLT) was also noted. The diagnosis, presence/absence
of CLT, as well as the absence of large lymphocytic
inﬁltrates of the PTC stroma were subsequently
conﬁrmed at histopathological revision by one of the
authors (A H). In addition, specimens of normal thyroid
tissue (nZ4), goiter (nZ1), and follicular thyroid
adenoma (nZ1) were collected at the same institution
and included as references in the immunohisto-
chemistry and ﬂuorescence in situ hybridization (FISH)
analysis. Samples were collected, and the study was
conducted with ethical permission obtained from the
local ethics committees.
Control samples for pyrosequencing constituted
11 PTC samples with BRAF T1799A mutation status
conﬁrmed by Sanger sequencing as previously reported
for ten of the cases by Soﬁadis et al. (29), as well as three
parathyroid adenomas. These samples had been
collected as fresh frozen samples at the Karolinska
University Hospital, Sweden, with informed consent and
ethical approval.
Pyrosequencing of the BRAF 1799TOA
mutation
Genomic DNA (gDNA) was extracted from FFPE
sections using a commercially available kit (Qiagen),
quantiﬁed with a Nano Drop 1000 Spectrophotometer
(Thermo Fisher Scientiﬁc Inc., Wilmington, DE, USA)
and used for pyrosequencing. Primers for PCR ampliﬁ-
cation of BRAF exon 15 and subsequent pyrosequen-
cing were designed using the Pyromark Q24 Software
2.0 (Qiagen) and commercially synthesized (bio-
mers.net GmbH, Ulm, Germany). The primer sequences
were as follows: forward 50-GGCCAAAAATTTAATCA-
GTGGAA-30, reverse 50-CTTCATAATGCTTGCTCTGAT-
AGG-30 (50-biotinylated) and sequencing 50-CCACT-
CCATCGAGATT-30. PCRs were performed using HotStar
Taq DNA polymerase kit (Qiagen) under the following
cycling conditions: 95 8C for 15 min, 35 cycles!(94 8C
for 30 s, 58 8C for 30 s, and 72 8C for 30 s) and ﬁnal
extension at 72 8C for 10 min. PCR products were
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(Biotium, Hayward, CA, USA). Subsequently, 30 ml
biotinylated PCR product was captured to ﬁltered probes
using PyroMark Q24 vacuum prep workstation,
ﬂushed, and released to Q24 plates with annealing
solution according to the protocol recommended by the
manufacturer. Plates with annealed samples were
processed in a Pyromark Q24 and the results were
analyzed using Pyromark Q24 Software 2.0 (Qiagen).
Pyrosequencing of additional DNA samples from PTC
cases with a BRAF 1799TOA mutation or wild-type
status previously determined by standard Sanger
sequencing was done as positive and negative controls
respectively (29). The accuracy of the pyrosequencing
was evaluated by analysis of 11 PTCs for which the
BRAF 1799TOA mutation determined by Sanger
sequencing was veriﬁed. Furthermore, the sensitivity
was demonstrated bydetection of the mutation in gDNA
diluted one,ﬁve,and ten times from one BRAF 1799TO
A mutation carrying PTC. The speciﬁcity of the method
was determined by detection of the wild-type BRAF
sequence only in the three parathyroid adenomas. The
cutoff level for BRAF 1799TOA was 10%.
Real-time PCR detection of RET/PTC1 and
RET/PTC3 fusion transcripts
Total RNA was isolated from all samples using RNA
isolation kit for FFPE tissue (Qiagen), according to
the protocol recommended by the manufacturer. cDNA
was synthesized from 100 ng total RNA using high-
capacity cDNA RT kit with random primers (Applied
Biosystems) according to the manufacturer’s descrip-
tion. Ampliﬁcation of cDNA was performed by RT-PCR
in a StepOnePlus PCR instrument using TaqMan
Universal PCR master mix (Applied Biosystems).
Primers and probes for RET/PTC1 and RET/PTC3
were synthesized according to Rhoden et al. (30). The
phosphoglycerate kinase 1 gene (PGK1)s e r v e da s
endogenous control. Two PTC samples with previously
reported expression of RET/PTC1 or RET/PTC3, respec-
tively (14), were included as positive controls, and
replacement of cDNA template with water constituted
the nontemplate control. RT-PCRs, including negative
and positive controls, were performed in duplicate
under standard conditions: 50 8C for 2 min followed
by 95 8C for 10 min and 45 cycles!(95 8C for 15 s,
60 8C for 1 min). Analysis of RT-PCR results was based
on the evaluation of ampliﬁcation curves for each
sample in comparison with positive controls (31).
Immunohistochemistry
MIB-1 index and expression of BCL2, cyclin A, and
cyclin D1 were analyzed on macroarray tissue slides of
the 70 PTCs as well as control thyroid samples by
immunohistochemistry using a previously described
protocol (29). The following primary antibodies were
used for antigen detection: monoclonal mouse anti-Ki-
67 (clone MIB-1; Dako, Stockholm, Sweden) at dilution
1:300; monoclonal mouse anti-CD45 (leukocyte com-
mon antigen, LCA) at 1:50 (clone 2B11CPD7/26;
Dako); monoclonal mouse anti-BCL2 (clone 124; Dako)
at 1:100; monoclonal rabbit anti-cyclin D1 (clone Sp4;
Dako) at 1:250; and monoclonal mouse anti-cyclin A
at 1:300 (clone E6E; Novocastra, Leica Biosystems,
Newcastle, UK). Macroarrays were prepared by joining
and re-embeddingof four to nine tissue samples in novel
FFPE blocks. For immunohistochemistry, 5 mm parafﬁn
sections were deparafﬁnized, rehydrated, and treated in
preheated citrate buffer pH 6.0 (Dako) at 95–99 8C for
20 min in a microwave oven. After incubation in 0.3%
hydrogen peroxide for 30 min and blocking in 1% BSA
with 0.01% sodium azide for 1 h at room temperature,
endogenous biotin was blocked using the Avidin/Biotin
Blocking Kit (SP-2001; Vector Laboratories, Burlin-
game, CA, USA). Primary antibody diluted in 1% BSA
was incubated overnight at 4 8Cf o l l o w e db yt h e
biotinylated secondary antibody horse antimouse IgG
at 1:700 (BA-1000/BA-2000, Vector Laboratories) for
45 min. Slides were subsequently incubated with the
avidin–biotin–peroxidase complex (Vectastain Elite Kit;
Vector Laboratories) for 45 min and diaminobenzidine
tetrahydrochloride for 6 min and counterstained with
hematoxylin for 3 min. Slides analyzed in parallel with
omission of the primary antibody served as negative
controls and showed expected absence of staining in all
cases. Positive controls constituted of tissue sections
from anonymous normal tissues of stomach, large and
small bowels, as well as lymphoid tissue, which revealed
expected staining patterns in accordance with infor-
mation provided by the antibody manufacturers. Anti-
cyclin A, anti-cyclin D, and anti-BCL2 were separately
incubated. MIB-1 was incubated separately as well as
coincubated with anti-LCA to allow optimal differen-
tiation between proliferating leukocytes and proliferat-
ing tumor cells.
Evaluation of immunohistochemistry
Slides were evaluated in a Zeiss Axioskop microscope
(Carl Zeiss, Jena, Germany) equipped with Zeiss Plan-
Neoﬂuar objective lenses, and images were captured
using a ProgRes C12 Plus camera and the ProgRes
Capture Pro 2.5 software program (Jenoptik, Jena,
Germany). For each case, the total number of PTC cells
was estimated (!16 objective magniﬁcation), and the
scoring was based on 1500–2000 cells. Non-PTC cells
were identiﬁed at microscopy and excluded from the
scoring of PTC cells. MIB-1 proliferation index and
cyclin A expression were determined by counting all
positive PTC cells in the areas where the number of
immunoreactive nuclei was the highest (hotspot) and
by calculating the proportion of positive nuclei. For
cyclin D1, only nuclear staining was considered and the
proportion of positive PTC cells estimated at
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was observed for BCL2 and the proportion of positive
PTC cells was estimated at microscopical evaluation.
Fluorescence in situ hybridization
Dual color FISH analysis was performed to evaluate
possible regional ampliﬁcation of the cyclin D1 locus
(CCND1) on FFPE sections from the 70 PTC cases.
A FISH probe kit (Abbott, Scandinavia) containing a
Spectrum Orange-labeled CCND1 probe (11q13) and a
Spectrum Green-labeled CEP11 probe for the D11Z1
alpha centromere satellite repeat was used (11p11.11-
q11). FISH was carried out using the Histology FISH
Accessory Kit (Dako) according to the recommen-
dations of the manufacturer. Visualization and scoring
of FISH signals were performed in a Zeiss Axioplan 2
imaging epiﬂuorescence microscope (Carl Zeiss) using
an !60 objective. For each case, a minimum of 200
interphase nuclei were scored, including only represen-
tative PTC cells with nonoverlapping nuclei and two
bright green CEP11 signals. The rationale for this
selection was to avoid misscoring of overlapping or
sectioned nuclei (32). Sections of an anonymous breast
carcinoma with validated CCND1 ampliﬁcation were
analyzed in parallel as positive controls.
Statistical analyses
Statistical calculations were performed using the data
analysis software Statistica version 10.0 (StatSoft
ScandinaviaAB,Uppsala,Sweden). TheMann–Whitney
U test was applied to compare the results in sample
groups. Spearman rank order correlation test was
performed to analyze possible relations between studied
parameters. Results with P values !0.05 were regarded
as statistically signiﬁcant.
Results
Clinical description of the post-Chornobyl
PTC cohort
The cohort consists of 70 patients who were exposed to
radioactivity from the Chornobyl accident in 1986 as
children or teenagers (%18 years) and who were
subsequently operated on for a primary PTC from
2004 to 2008. Clinical characterization of patients and
tumors was based on medical records and histopatho-
logical revision of PTC slides as summarized in Table 1.
The mean age of patients was 10.4 years at the time of
the Chornobyl accident and 30.4 years at the time
of surgery. Female patients were overrepresented
6.8 times compared with male patients (87 vs 13%).
For 52 patients, the size of PTC was %2c m i n
maximum diameter, whereas 18 patients had a PTC
O2 cm. Metastases to local lymph nodes were detected
at the time of diagnosis in 19 cases (27%). However,
distant metastases were not observed. In 16 of the 70
PTC tumors, coexisting CLT was observed (referred to as
PTC/CLT), whereas 54 cases did not show this feature
(PTC only). Cases with PTC only and PTC/CLT did not
differ signiﬁcantly concerning gender, age at exposure
and surgery, tumor size, or metastasis. Similarly, no
statistically signiﬁcant difference was observed when
tumor size was compared with gender, age, metastasis,
or presence of CLT.
Frequent occurrence of the common BRAF
mutation and/or RET/PTC rearrangements
All 70 cases were screened for the common BRAF
mutation in exon 15 using pyrosequencing (Fig. 1). In
total, 26 (37%) tumors exhibited a base substitution
1799TOA predicted to result in the V600E missense
mutation (Table 2). Comparison of BRAF mutation
status with clinical characteristics did not reveal any
signiﬁcant associations for the parameters gender, sex,
age, or lymph node metastasis. However, 24 of the 26
BRAF mutated cases had been classiﬁed as PTC only
while two cases were of PTC/CLT type. Hence, BRAF
mutations were 3.5 times less frequent in the PTC/CLT
group (2/16; 12%) compared with PTC only (24/54;
44%) (PZ0.02). The cutoff level of 10% was applied to
classify cases as positive or negative. Overall, positive
cases exhibited proportions of mutant allele, which
varied between 12 and 44%. The proportion of mutant
alleles was not found to be different between PTC-only
cases (mean 28%, range12–44%) and the two PTC/CLT
cases (18 and 34%).
The presence of a RET/PTC1 or RET/PTC3 rearrange-
ment was assessed by analysis of ampliﬁcation curves
Table 1 Clinical characteristics for the 70 post-Chorno-
byl PTC patients.
Parameter Observation
Informative cases (n)7 0
Gender
Male 9
Female 61
Ratio (female:male) 7:1
Age at diagnosis (years)
Mean 30.4
Median (range) 31 (19–39)
Age at Chornobyl (years)
Mean 10.4
Median (range) 12 (!1–18)
Tumor size (cm)
Mean 1.9
Median (range) 1.7 (1–6)
Local lymph node metastasis
No. of cases 19 (27%)
Distant metastasis
No. of cases 0 (0%)
Chronic lymphocytic thyroiditis
(CLT)
No. of cases with PTC/CLT 16 (23%)
No. of cases with PTC only 54 (77%)
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showed rearrangement of RET in which RET/PTC1 was
validated in 20 cases and RET/PTC3 in four cases
(Table 2). Hence, these rearrangements were commonly
observed in the cohort and RET/PTC1 was ﬁve times
more frequent than RET/PTC3. Associations between
RET/PTC1 or RET/PTC3 and clinical parameters were
not observed.
A genetic alteration commonly associated with PTC,
i.e. a BRAF 1799TOAm u t a t i o no raRET/PTC
rearrangement, was detected in 46 of the 70 PTCs.
These included 22 cases with the BRAF 1799TOA
mutation only, 17 with a RET/PTC1 rearrangement only,
three with RET/PTC3 only, three with BRAF 1799TOA
and RET/PTC1, and one case with BRAF 1799TOAa n d
RET/PTC3. In 24 tumors, neither BRAF 1799TOAn o r
a RET/PTC rearrangement was revealed.
MIB-1 proliferation index
Proliferation index was determined using MIB-1
immunohistochemistry and counting of cells with
positive nuclei (Fig. 3 and Table 2). Lymphocytes used
as internal controls showed strong nuclear staining in
more than 50% of the cells. Given the frequent
occurrence of lymphocytes in the PTC specimens,
including 16 cases with PTC/CLT, we performed double
staining with LCA to facilitate the distinction bet-
ween proliferative lymphocytes and tumor cells (Fig. 3).
All 70 PTC cases were positive, while normal thyroid
tissues included in the FFPE macroarrays of the PTC
cohort were completely negative (Table 3). The mean
MIB-1 index for the entire cohort determined by
combined MIB-1/LCA immunohistochemistry was
0.8% (range 0.05–4.5%). For comparison, MIB-1
index was also determined by regular counting of
MIB-1-stained slides, applying visual distinction
between proliferating lymphocytes and proliferating
tumor cells. This analysis showed that 65/70 PTCs
were positive with a mean MIB-1 indexof 1.5% (median
1.0%, range 0–7.5%). Comparison of MIB-1 index with
clinical characteristics did not reveal statistically
signiﬁcant associations for the MIB-1/LCA- or MIB-1-
based analyses.
Expression of cyclin A in relation to size of PTC
Cyclin A expression was determined by scoring of
immunohistochemical nuclear expression (Fig. 4A and
B). In normal thyroid tissue, no staining was observed
(Table 3). In the PTC cohort, the mean level of
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A
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Figure 1 Analysis of the common mutation 1799TOA in exon 15 of
BRAF by pyrosequencing. (A) Wild-type BRAF sequence in a case
of PTC/CLT, revealed as a large A peak without a subsequent
abnormal T peak in the shaded area of the pyrogram. (B) Detection
of a 1799TOA mutation in a case of PTC only, revealed as a
decreased peak A combined with an elevated peak T (marked by
asterisk). (C and D) Photomicrographs of hematoxylin-stained
slides show histopathological ﬁndings in (C) a case of PTC/CLT and
(D) a PTC only without CLT.
Table 2 Summary of genetic and immunohistochemical ﬁndings in
the 70 cases of post-Chornobyl PTCs studied. Cutoff level for
positive cases was 0% for all antibodies.
Parameter studied
Observation
in 70 PTCs
BRAF 1799TOA mutation
No. with 1799TOA 26 (37%)
No. with wild-type 44 (63%)
RET/PTC1 rearrangement
No. with RET/PTC1 20 (29%)
No. without rearrangement 50 (71%)
RET/PTC3 rearrangement
No. with RET/PTC3 4 (6%)
No. without rearrangement 66 (94%)
BRAF and RET/PTC
No. with 1799TOA and RET/PTC1 3 (4%)
No. with 1799TOA and RET/PTC3 1 (1%)
No. with BRAF wild-type and no RET/PTC 22 (31%)
MIB-1 proliferation index (MIB-1 only)
Mean proportion positive nuclei 1.5%
Median proportion positive nuclei 1.0%
MIB-1 proliferation index (MIB-1Canti-LCA)
Mean proportion positive nuclei 0.8%
Median proportion positive nuclei 0.7%
No. of positive cases 70 (100%)
Cyclin A immunohistochemistry
Mean proportion positive cells 0.7%
Median proportion positive cells 0.4%
No. of positive cases 64 (92%)
Cyclin D1 immunohistochemistry
Mean proportion positive nuclei 27%
Median proportion positive nuclei 20%
No. of positive cases 68 (97%)
BCL2 immunohistochemistry
Mean proportion positive cells 48%
Median proportion positive cells 50%
No. of positive cases 53 (76%)
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3.9%. Six PTC cases were negative with lack of
immunoreactive PTC cells. Among the 64 tumors
with cyclin A expression, 48 cases showed !1% posi-
tive cells and 16 exhibited 1–4% positive cells according
to the previously published recommendations of
classiﬁcation (33). When compared with the clinical
characteristics, we found that the expression of cyclin A
differed signiﬁcantly according to the size of the PTC.
Speciﬁcally, expression of cyclin A was higher in PTCs
O2 cm than in PTCs %2c m( PZ0.004; mean 1.2 vs
0.6% respectively). No other association between cyclin
A expression and clinical parameters was noted.
Frequent expression of cyclin D1 without
associated CCND1 ampliﬁcation
Cyclin D1 was evaluated concerning both protein
expression and regional ampliﬁcation of the CCND1
locus. Cyclin D1 immunohistochemistry was negative
in normal thyroid tissue (Table 3). In the PTC cohort,
we detected nuclear immunoexpression of cyclin D1
(Fig. 4C and D), and in addition, cytoplasmic staining
was also noted in some cases, which was not included
in the scorings. The mean proportion of positive PTC
cells was 27% ranging from 0 to 90%. Sixty-eight cases
showed expression with !10% positive cells in 25
cases, 10–49% positive cells in 25 cases, and R50%
positive cells in the remaining 18 cases according to the
previously applied cutoff levels for subgroups (34).N o
association was detected between the expression level
and clinical characteristics. FISH analysis in normal
thyroid tissue showed two signals for the CCND1 probe.
Moreover, FISH analyses revealed two bright green and
two bright orange signals in all representative PTC cells
for all cases. This observation suggests that the observed
cyclin D1 expression was not a consequence of CCND1
regional ampliﬁcation.
Expression of BCL2
Immunohistochemical expression of BCL2 was ident-
iﬁed in the majority of PTC cases and observed in
normal thyroid tissue and goiter (Table 3 and Fig. 4E
and F). Among the 70 PTC cases, the mean level of
expression was 48% ranging from 0 to 100% posi-
tively stained cells. Altogether, 53 cases exhibited BCL2
expression, in 1–25% of the cells for 13 cases, in
26–50% of cells for eight cases, and in O50% of cells
in 32 cases. The remaining 17 cases were negative
without immunoreactive PTC cells. Normal thyroid
tissue and goiter were strongly positive with O75%
positively stained cells in 4/5 samples (Table 3). No
association with clinical parameters was identiﬁed.
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Figure 2 Detection of a RET/PTC1 fusion by reverse-transcribed
PCR. The ampliﬁcation curves 1 and 3 reveal the presence of
RET/PTC1 in a PTC case (curve 1), and the positive control with
previously validated RET/PTC1 (curve 3). Curves 2 and 4
correspond to ampliﬁcation of the endogenous control PGK1. AB
CD
EF
Figure 3 Analysis of MIB-1 proliferation index by
immunohistochemistry using MIB-1 only or double staining with
MIB-1 and anti-LCA. (A and B) A case of PTC/CLT shown after
regular MIB-1 staining with immunoreactivity in PTC cells and
proliferating lymphocytes. (C and D) The same case after double
staining with MIB-1 and anti-LCA showing proliferative PTC cells
(brown), proliferative lymphocytes (red and brown), and nonproli-
ferative lymphocytes (red). (E and F) A case of PTC only without
CLT after MIB-1 and anti-LCA double staining. Slides are shown in
different magniﬁcations using (A, C and E) objective !16; (B) !40;
or (D and F) !63.
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immunohistochemical phenotypes
Possible relationships between the genetic ﬁndings and
immunohistochemical parameters assessed in the
study were determined by Spearman’s rank order
correlation test. Several statistically signiﬁcant obser-
vations were made. MIB-1 index showed a positive
correlation with expression levels of both cyclin A
(rZ0.38, P!0.05) and cyclin D1 (rZ0.34, P!0.05).
Cyclin D1 expression levels showed a positive corre-
lation with cyclin A expression (rZ0.39, P!0.05) and
a negative correlation with the presence of RET/PTC1
(rZK0.26, P!0.05). Finally, a positive correlation was
found between BRAF mutation and BCL2 expression
(rZ0.24, P!0.05). However, for all identiﬁed corre-
lations, Cohen’s effect size was !0.5, suggesting that
the detected correlations are relatively weak.
Discussion
In this study, we present a comparably large cohort of
patients operated on for PTC, who were exposed to
radioactive fallout in their childhood or as teenagers
after the Chornobyl nuclear plant accident in 1986. The
clinical features do not appear to be signiﬁcantly
different compared with other cohorts of PTC patients
who were not exposed to radioactivity. Whether this
cohort has a signiﬁcantlydifferent clinical course awaits
follow-up; however, the time allowing for prognostic
evaluation is presently too short. One weakness of the
study is the lack of a control group in the experiments,
in order to shed light over the speciﬁcity of the ﬁndings.
A control group, however, would require recruitment
from a totally different age group, or from another,
noncontaminated, geographic area with a different
demographic proﬁle. Therefore, we decided not to
include a control group in the experiments but to
compare all the ﬁndings with existing data on similar
cohorts found in the literature.
To further characterize the cohort, we have applied
some established markers often used in the work-up of
PTC patients. Some of these markers are summarized
in Table 4, containing details of observations from
published studies of postradiation PTCs and nonradia-
tion-associated PTCs. The frequency of BRAF mutation
in the entire cohort was 37%, which is similar to many
series of nonradiation PTC (35, 36). By contrast, BRAF
mutation has been less frequently observed in post-
radiation PTC, i.e. 4–24% (Table 4). It is worth noticing
that BRAF mutation was signiﬁcantly underrepre-
sented among the patients with PTC/CLT compared
with PTC only, which is in accordance with the previous
studies (37, 38). The ﬁnding may also reﬂect the facts
that BRAF mutation has been associated with more
aggressive PTC (39, 40) while the presence of CLT in
PTC seems to lead to a better prognosis (41, 42). Thus,
the fewer occurrences of BRAF mutation in PTC/CLT
patients may also be connected to good prognosis.
In this study, we determined the proportion of BRAF
mutant alleles to be below 50% (mean 28%), which
could be related to contamination of nontumor cells in
the samples studied as well as intratumoral hetero-
geneity of the BRAF mutation. The latter situation was
recently shown by Guerra et al. (43). In our study,
histopathological examination of all samples indicated a
high PTC representativity with minor proportions of
non-PTC cells. This was also true for the PTC/CLTcases
in which large areas of lymphocytic inﬁltrations were
not observed. Taken together with the sensitivity of the
Table 3 Expression of MIB-1, BCL2, cyclin A, and cyclin D1 in
nonmalignant tissues. Cutoff level for positive cases was 0% for all
antibodies.
Parameter MIB-1 BCL2 Cyclin A Cyclin D1
Normal thyroid (nZ4)
Negative 4 0 4 4
Positive 0 4 0 0
Follicular thyroid
adenoma (nZ1)
Negative 0 0 0 0
Positive 1 1 1 1
Goiter (nZ1)
Negative 1 0 1 1
Positive 0 1 0 0
AB
CD
EF
Figure 4 Immunohistochemical analysis of cyclin A, cyclin D1,
and BCL2 expression shown in small (objective !16, left) or
large magniﬁcation (objective !40, right). (A and B) Cyclin A
expression of 2.8% in a large-sized PTC O2 cm; (C and D) cyclin
D1 expression of 70% in a sample of PTC only; and (E and F) BCL2
expression of 90% in a PTC-only sample.
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observed in gDNA of a PTC after dilution), our
observations would support intratumoral heterogeneity
for BRAF 1799TOA.
RET/PTC rearrangements in the form of RET/PTC1
and RET/PTC3 were demonstrated in 29 and 6%
respectively. While previous studies on RET/PTC have
reported highly varying frequencies from 5 to 87%
(Table 4), postradiation cases have generally shown
the highest frequencies. In comparison with these
reports, our ﬁnding of 34% RET/PTC positivity falls
within the lower range of postradiation PTC and is
comparable to the highest frequencies among non-
radiation PTCs (15, 37, 44). However, with regard to
the speciﬁc fusion type involved, we found RET/PTC1 to
be ﬁve times more common than RET/PTC3, which is in
contrast to other reported postradiation PTCs but in
agreement with nonradiation PTCs (45). Overall, the
presence of RET/PTC is usuallyconsidered to be a sign of
poor prognosis in PTC. Moreover, RET/PTC accom-
panied by a BRAF 1799TOA mutation is associated
with a high risk of disease recurrence and metastases.
In the current study, co-occurrence of RET/PTC and
BRAF mutation was detected in four PTCs. Although
the clinical features at surgery were not indicative of
poor prognosis, these cases should be considered for
close follow-up for early recognition of signs for PTC
recurrence as reported in the literature (13, 39).
Moreover, different frequencies of RET/PTC1 and
RET/PTC3 were reported in childhood post-Chornobyl
PTC. However, these studies showed signiﬁcant vari-
ation of these genetic aberrations depending on the
histopathological type of PTC. Thus, RET/PTC1 was
associated with the classical and diffuse sclerosing
variants of PTC, whereas RET/PTC3 was associated
with the solid follicular type (46, 47). On the other
hand, the solid follicular type of PTC is more common in
pediatric patients, while the classical PTC is more
common in adults (47). The patient’s age is also an
important factor for the BRAF 1799TOA mutation,
which is commonly found in adult patients, but is rare
in childhood PTC, which is consistent with our ﬁnding
(9, 10).
MIB-1 index is increasingly used in the immuno-
histochemical work-up of several cancer types. The
MIB-1 MAB is directed toward the nuclear antigen
Ki-67 and is used for identiﬁcation of proliferative cells
and areas of tumors with a high degree of proliferation.
This index has been suggested to predict the prognosis
in many cancer varieties, including PTC (19, 20, 21).
PTC exhibits varying proportions of inﬁltrating lym-
phocytes, which was pronounced in the PTC/CLT
entity and was less abundant in several PTC-only
cases. As MIB-1 immunostaining targets proliferating
cells, both proliferating lymphocytes and tumor cells
will be stained, with associated risks of misclassiﬁcation
and false-positive or negative scoring as a consequence.
To achieve optimal scoring conditions, we used double
staining with MIB-1 and LCA in addition to regular
MIB-1 staining of all cases. Typical examples of the
result are illustrated in Fig. 3. Overall, lower MIB-1
proliferation index was revealed using the MIB-1/LCA-
based analysis compared with MIB-1 only (mean 0.8 vs
1.5%; Table 2). If substantiated in follow-up studies, the
observations suggest that double staining of MIB-1 and
LCA should be considered for use in clinical routine
work-up of PTC instead of regular MIB-1-only analysis.
Associations between MIB-1 proliferative index and
clinical features were not observed. In the ﬁve cases
with MIB-1 index above the R1.85% border applied in
our previous studies (19, 20), signs of aggressive clinical
features were not observed concerning histopathologi-
cal and clinical features present at the time of surgery.
However, in some previous publications, increased
MIB-1 index in PTC has been associated with adverse
outcome during follow-up (19, 20, 22). Possible
prognostic implications of MIB-1 index in this cohort
cannot be presently assessed given the lack of follow-up.
Expression of the antiapoptotic protein BCL2 was
observed in the majority of PTCs. All normal thyroid
tissue samples and 53/70 PTCs expressed BCL2,
suggesting that BCL2 could have a protective role to
prevent apoptosis in normal thyroid, which is partly lost
in malignancy. In contrast to a previous study, no
correlation was observed between BCL2 expression and
MIB-1 index in PTC/CLTcases (48). However, a positive
correlation was observed between BCL2 expression and
BRAF mutation. Although this correlation was not
strong, it is consistent with the study by Preto et al. (49),
showing inhibition of BCL2 in PTC cell lines treated
with the BRAFand kinase inhibitor sorafenib. Moreover,
the lack of association between clinical features and
BCL2 expression in our cohort is consistent with the
observations by Siironen et al. (18).G i v e nt h a t
phosphorylation is needed for the antiapoptotic effect
of BCL2 (50), further determination of phosphorylated
BCL2 expression levels would add more information
about the antiapoptotic status of PTC.
We observed signiﬁcantly elevated expression of
cyclin A in PTCs larger than 2 cm. Previous studies of
this protein have reported overexpression in poorly
differentiated and undifferentiated thyroid cancers,
indicating a role in thyroid carcinoma de-differentiation
(25). Our ﬁnding of an association between cyclin A
expression and tumor size implies that cyclin A could
have prognostic value in irradiation-associated PTC;
however, much longer follow-up is required to prove or
disprove this. Although the possible utility of cyclin A
for routine clinical practice is presently unclear, the
observed association warrants further investigation
of cyclin A in relation to follow-up.
Cyclin D1 expression was detected in the majority
of PTCs. This was not accompanied by regional
ampliﬁcation of the CCND1 locus, suggesting that
cyclin D1 is deregulated at the transcriptional, trans-
lational, or posttranslational level. In our scorings,
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suggested elsewhere (34). However, we have also
observed cytoplasmic staining, which could be
explained by cytoplasmic sequestration of cyclin D1
due to inhibition of its transportation to the nucleus
(51, 52). Elevated expression of cyclin D1 was found to
be correlated with elevated MIB-1 index, an association
that was also demonstrated by Alama et al. (53) in
meningioma. No other associations to clinical or
pathological features were observed, which is in
agreement with the previous studies (34, 54). However,
others have reported that cyclin D1 overexpression may
be a prognostic marker for PTC (55, 56).
In summary, we report a cohort of adult PTC patients
exposed to the radioactive fallout from the Chornobyl
accident during their childhood or as teenagers. Our
results from genetic and molecular characterization
suggest that this cohort is characterized by frequent
BRAF 1799TOA mutation and RET/PTC1 rearrange-
ment as well as low proliferation, which are partly
overlapping and partly distinguishing from other
reported cohorts of postradiation- and nonradiation-
related PTC. Moreover, BRAF mutation was signi-
ﬁcantly underrepresented in the PTC/CLT group, and
cyclin A expression was associated with tumor size in
this entity. Long-term follow-up in this cohort will
eventually identify possible effects on patient outcome
in this patient group.
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